Keyphrases
Randomized Trial
100%
Patients with Prostate Cancer
100%
Degarelix
100%
Leuprolide
100%
Cardiovascular Safety
100%
Gonadotropin-releasing Hormone
80%
Gonadotropin-releasing Hormone Antagonist
80%
Major Adverse Cardiovascular Events
60%
Prostate Cancer
40%
Atherosclerotic Cardiovascular Disease (ASCVD)
40%
Myocardial Infarction
20%
Hazard Ratio
20%
Cardiovascular Disease
20%
Randomized Clinical Trial
20%
Cancer Disease
20%
Open-label Trial
20%
Advanced Prostate Cancer
20%
Localized Prostate Cancer
20%
Locally Advanced Disease
20%
Prospective Randomized Trial
20%
Metastatic Disease
20%
Baseline Characteristics
20%
Number of Participants
20%
First International
20%
Number of Events
20%
Unique Identifier
20%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Degarelix
100%
Leuprorelin
100%
Cardiovascular Disease
66%
Gonadorelin Agonist
66%
Gonadorelin Antagonist
66%
Coronary Artery Atherosclerosis
33%
Heart Infarction
16%
Disease
16%
Randomized Clinical Trial
16%
Open-Label Trial
16%
Metastasis
16%